For the Inventor, By the Inventor

Enter assignee name

Centro De Inmunologia Molecular

USPTO Granted Patents = 22

CIPO Patents = 13

EPO Patents = 20

Forward Citations = 466

Loading Chart...

Loading Chart...

90 inventors (with patents filed for the assignee):

Rolando Perez Rodriguez (9 out of 16 patents)

Jose Enrique Montero Casimiro (4 out of 12 patents)

Kalet León Monzón (4 out of 7 patents)

4. Circe Mesa Pardillo (4 out of 7 patents)

5. Luis Enrique Fernández Molina (4 out of 7 patents)

6. Pradip Nair (3 out of 11 patents)

7. Sundaraj David Rajkumar (3 out of 6 patents)

8. Kedarnath Nanjund Sastry (3 out of 19 patents)

9. Josefa Lombardero Valladares (3 out of 9 patents)

10. Ramakrishnan Melarkode (3 out of 21 patents)

11. Monalisa Chatterji (3 out of 7 patents)

12. Laxmi Adhikary (3 out of 12 patents)

13. Hema Balasubramanian (3 out of 6 patents)

14. Tania Carmenate Portilla (3 out of 5 patents)

15. Audry Fernández Gómez (3 out of 3 patents)

22 patents: Sort by Forward Citations

1. 12312388 - Method for increasing the secretion levels of interleukin 2 and muteins thereof by introducing a point mutation (2025-05-27),

2. 12280109 - Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines (2025-04-21),

3. 12019073 - Method for the treatment of patients with carcinomas (2024-06-25),

4. 11981743 - Monoclonal antibody and a method thereof (2024-05-14),

5. 11926654 - Fusion proteins composed of an interleukin-2 mutein and type I interferon (2024-03-12),

6. 11806396 - Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines (2023-11-07),

7. 11766462 - Ganglioside GM3-containing nanoparticles as immunomodulators (2023-09-26),

8. 10669346 - Monoclonal antibody and a method thereof (2020-06-02),

9. 10457747 - Method for obtaining high-yield, stable expression cell clones and antibody molecules obtained thereby (2019-10-29),

10. 9701730 - TGFβ-derived polypeptides and uses thereof (2017-07-11),

11. 9670285 - Monoclonal antibody and a method thereof (2017-06-06),

12. 8759486 - Immunomodulatory interleukin-2 polypeptides and methods of treating melanoma (2014-06-24),

13. 8563003 - Method for the treatment of malignant and infectious chronic diseases (2013-10-22),

14. 8470322 - Anti sulfatides and anti sufated proteoglycans antibodies and their use (2013-06-25),

15. 7744871 - Immunotherapeutic combination for the treatment of tumors that over-express receptors with tyrosine kinase activity (2010-06-29),

Centro De Inmunologia Molecular (CIM) is a renowned Cuban biopharmaceutical company specializing in the development and production of innovative cancer immunotherapy drugs. With a strong focus on research and development, CIM has made significant contributions to the field of biotechnology and is recognized globally for its breakthrough treatments. For more information, please visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

22 Patents

#2 in Havana

#2 in Cuba

#27,863 in the World

Centro De Inmunologia Molecular

Forward Citations = 466

90 inventors:

Rolando Perez Rodriguez (9 out of 16 patents)

Jose Enrique Montero Casimiro (4 out of 12 patents)

Kalet León Monzón (4 out of 7 patents)

4. Circe Mesa Pardillo (4 out of 7 patents)

5. Luis Enrique Fernández Molina (4 out of 7 patents)

Please report any incorrect information to support@idiyas.com

Loading…